Cited by 3Hyperglycemia and glycemic control in critically ill and hospitalized patientsDiabetes Management and ResearchDiabetes Treatment and Management

Weight-based insulin during and after intravenous insulin infusion reduces rates of rebound hyperglycemia when transitioning to subcutaneous insulin in the medical intensive care unit

Zhou, Keren, Buehler, Lauren Anne, Zaw, Tin, Bena, James, Lansang, M. Cecilia·2022·Endocrine Practice

Abstract

Objective Hyperglycemia often occurs after the transition from intravenous insulin infusion (IVII) to subcutaneous insulin. Weight-based basal insulin initiated earlier in the course of IVII in the medical intensive care unit (MICU), and a weight-based basal-bolus regimen after IVII, can potentially improve post-IVII glycemic control by 48 hours. Methods This prospective study included 69 patients in MICU who were on IVII for ≥24 hours. Exclusions were end-stage renal disease, type 1 diabetes mellitus, and the active use of vasopressors. The intervention group received weight-based basal insulin (0.2-0.25 units/kg) with IVII and weight-based bolus insulin after IVII. The control group received current care. The primary end points were glucose levels at specific time intervals up to 48 hours after IVII. Results There were 25 patients in the intervention group and 44 in the control group. The mean age of the patients was 59 ± 15 years, 32 (47%) were men, and 52 (78%) had prior diabetes mellitus. The 2 groups were not different (acute kidney injury/chronic kidney disease, pre-existing diabetes mellitus, illness severity, or nothing by mouth status after IVII), except for the steroid use, which was higher in the control group than in the intervention group (34% vs 12%, respectively). Glucose levels were not lower until 36 to 48 hours after IVII (166.8 ± 39.1 mg/dL vs 220.0 ± 82.9 mg/dL, P Conclusion The addition of weight-based basal insulin during, and basal-bolus insulin immedi…

Integrity signals

Registry

Crossref · 10.1016/j.eprac.2021.10.003

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Emerging data from studies in people with hyperglycemia with and without diabetic ketoacidosis (DKA) show that the administration of a low dose (0.15-0.3 units/kg) of basal insulin analog in addition to intravenous insulin infusion may reduce the duration of insulin infusion and length of hospital stay and prevent rebound hyperglycemia without increased risk of hypoglycemia.

    “Emerging data from studies in people with hyperglycemia with and without diabetic ketoacidosis (DKA) show that the administration of a low dose (0.15-0.3 units/kg) of basal insulin analog in addition to intravenous insulin infusion may reduce the duration of insulin infusion and length of hospital stay and prevent rebound hyperglycemia without increased risk of hypoglycemia (64)(65)(66)(67).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zhou, K., Buehler, L. A., Zaw, T., Bena, J., & Lansang, M. C.
Affiliations
Cleveland Clinic (US)
Corresponding author
Zhou, Keren
Venue
Endocrine Practice
Publisher
Elsevier BV
Published
2022-02
Volume
28
Issue
2
Pages
173-178
ISSN
1530-891X (ISSN-L)
OpenAlex
W3207106114
Cited by
3
References
5
Citations by year
2026: 1 · 2025: 2
FWCI
0.00
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrine Practice (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Lerner Research Institute, Cleveland Clinic
  • Cleveland Clinic
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
intravenous insulin infusion, rebound hyperglycemia, glycemic control, medical intensive care unit, multiple daily insulin injections, hypoglycemia, critically ill patients, hyperglycemia management, corticosteroid use, body mass index, nutritional status, HbA1c, diabetes mellitus, acute kidney injury
MeSH terms
Adult, Aged, Blood Glucose, Humans, Hyperglycemia, Hypoglycemic Agents, Infusions, Intravenous, Insulin, Intensive Care Units, Male, Middle Aged, Prospective Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review